We found here that systemically administered IL-23 could elicit pain and arthritis in a mBSA-injected joint and that neutralization of TNF and deletion of Csf2 and Ccl17 prevented the pain and reduced the associated arthritis. This evidence concerns the gene CCL17 and Arthritis.